DNA Damage in Blood Lymphocytes in Patients After 177Lu Peptide Receptor Radionuclide Therapy

European Journal of Nuclear Medicine and Molecular Imaging- Germany

doi 10.1007/s00259-015-3083-9

Full Text

Abstract

Available in

Date

Authors

Publisher

Springer Science and Business Media LLC

Related search

Predictors of Long-Term Outcome in Patients With Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2014English

Peptide Receptor Radionuclide Therapy

Best Practice and Research in Clinical Gastroenterology
Gastroenterology
2005English

Peptide Receptor Radionuclide Therapy

2007English

New Developments in Peptide Receptor Radionuclide Therapy

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2018English

Reply: Peptide Receptor Radionuclide Therapy in the United States

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2012English

Peptide Receptor Radionuclide Therapy in Patients With Medullary Thyroid Carcinoma: Predictors and Pitfalls

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Joint Guidance on Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2013English

Parameters to Predict Progression Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2019English

Diagnosis of Men-I Syndrome on 68Ga-Dotanoc PET-CT and Role of Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate

International Journal of Endocrinology and Metabolism
EndocrinologyMetabolismDiabetes
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy